These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11148991)

  • 1. A novel treatment for refractory primary biliary cirrhosis?
    Miyaguchi S; Ebinuma H; Imaeda H; Nitta Y; Watanabe T; Saito H; Ishii H
    Hepatogastroenterology; 2000; 47(36):1518-21. PubMed ID: 11148991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
    Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R; Tur-Kaspa R
    J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.
    Nakai S; Masaki T; Kurokohchi K; Deguchi A; Nishioka M
    Am J Gastroenterol; 2000 Jan; 95(1):326-7. PubMed ID: 10638623
    [No Abstract]   [Full Text] [Related]  

  • 5. Bezafibrate treatment: a new medical approach for PBC patients?
    Kanda T; Yokosuka O; Imazeki F; Saisho H
    J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.
    Akbar SM; Furukawa S; Nakanishi S; Abe M; Horiike N; Onji M
    J Gastroenterol; 2005 Feb; 40(2):157-63. PubMed ID: 15770399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
    Lens S; Leoz M; Nazal L; Bruguera M; Parés A
    Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
    Kita R; Takamatsu S; Kimura T; Kokuryu H; Osaki Y; Tomono N
    J Gastroenterol; 2006 Jul; 41(7):686-92. PubMed ID: 16933007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bezafibrate in primary biliary cirrhosis: a pilot study.
    Ohmoto K; Mitsui Y; Yamamoto S
    Liver; 2001 Jun; 21(3):223-4. PubMed ID: 11422787
    [No Abstract]   [Full Text] [Related]  

  • 11. Is bezafibrate histologically effective for primary biliary cirrhosis?
    Yano K; Kato H; Morita S; Takahara O; Ishibashi H; Furukawa R
    Am J Gastroenterol; 2002 Apr; 97(4):1075-7. PubMed ID: 12003404
    [No Abstract]   [Full Text] [Related]  

  • 12. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New weapon for primary biliary cirrhosis from Japan.
    Zeniya M
    J Gastroenterol; 2003; 38(6):619-20. PubMed ID: 12858848
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Walker LJ; Newton J; Jones DE; Bassendine MF
    Hepatology; 2009 Jan; 49(1):337-8; author reply 338. PubMed ID: 19035342
    [No Abstract]   [Full Text] [Related]  

  • 16. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis.
    Ide T; Sata M; Nakano H; Suzuki H; Tanikawa K
    Hepatogastroenterology; 1997; 44(18):1569-73. PubMed ID: 9427024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.
    Hidaka M; Iwasaki S; Matsui T; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Kiyokawa T; Takahashi M; Saibara T; Onishi S; Kawano F
    Bone Marrow Transplant; 2010 May; 45(5):912-8. PubMed ID: 19802024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy.
    Miyaguchi S; Oda M; Saito H; Ishii H
    Hepatogastroenterology; 1998; 45(23):1457-61. PubMed ID: 9840083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.